Scholarlink

Purpose <p>This randomized controlled trial evaluated the efficacy of a multidisciplinary, mobile health (mHealth) supportive care program designed to alleviate symptom burden and enhance self-efficacy in post-treatment breast cancer survivors (BCS). Secondary outcomes included quality of life (QoL), coping strategies, and inflammatory biomarkers.</p> Methods <p>We conducted a single-blind, randomized controlled trial involving 108 BCS. Participants were allocated to either a 3-month mHealth intervention (<i>n</i> = 54) delivered via the "ThrivePath" app or a routine care control group (<i>n</i> = 54). The app provided structured symptom monitoring, educational resources, and personalized support. Outcomes were assessed at baseline, 3&#xa0;months (post-intervention), and 6&#xa0;months (follow-up) and analyzed using linear mixed models.</p> Results <p>Compared to controls, the intervention group showed a significant reduction in symptom burden (<i>β</i> = -9.44, <i>p</i> &lt; 0.001) and a significant increase in self-efficacy (<i>β</i> = 5.45, <i>p</i> &lt; 0.001). The program also improved QoL, enhanced confrontation coping, and led to a significant reduction of pro-inflammatory cytokines (IL-1β, IL-2, IL-6, TNF-α) while preserving anti-inflammatory IL-10 levels.</p> Conclusions <p>The "ThrivePath" mHealth program is an effective, scalable intervention for post-treatment breast cancer survivors. It significantly reduces symptom burden and modulates inflammatory processes while boosting self-efficacy, offering an evidence-based model for delivering comprehensive survivorship care.</p> Implications for Cancer Survivors <p>The ThrivePath program provides a practical and accessible tool for survivors to manage their health following active treatment. By facilitating access to evidence-based resources and enabling direct communication with a care team, the program can help alleviate persistent symptoms, build confidence in self-management, and improve overall quality of life during the transition to survivorship.</p> <p>Trial registration: ChiCTR2500108128.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of an integrated mHealth supportive care program on symptom burden and self-efficacy in post-treatment breast cancer survivors: a randomized controlled trial

  • 期刊论文

  • 发表日期：

    2026年2月19日

查看全文
  • Yingjie Yao,
  • Xiangyu Liu,
  • Yuansi Huang,
  • Andy S. K. Cheng,
  • Qinqin Cheng,
  • Huixia Wu,
  • Ruiqiong Xiao

摘要

Purpose

This randomized controlled trial evaluated the efficacy of a multidisciplinary, mobile health (mHealth) supportive care program designed to alleviate symptom burden and enhance self-efficacy in post-treatment breast cancer survivors (BCS). Secondary outcomes included quality of life (QoL), coping strategies, and inflammatory biomarkers.

Methods

We conducted a single-blind, randomized controlled trial involving 108 BCS. Participants were allocated to either a 3-month mHealth intervention (n = 54) delivered via the "ThrivePath" app or a routine care control group (n = 54). The app provided structured symptom monitoring, educational resources, and personalized support. Outcomes were assessed at baseline, 3 months (post-intervention), and 6 months (follow-up) and analyzed using linear mixed models.

Results

Compared to controls, the intervention group showed a significant reduction in symptom burden (β = -9.44, p < 0.001) and a significant increase in self-efficacy (β = 5.45, p < 0.001). The program also improved QoL, enhanced confrontation coping, and led to a significant reduction of pro-inflammatory cytokines (IL-1β, IL-2, IL-6, TNF-α) while preserving anti-inflammatory IL-10 levels.

Conclusions

The "ThrivePath" mHealth program is an effective, scalable intervention for post-treatment breast cancer survivors. It significantly reduces symptom burden and modulates inflammatory processes while boosting self-efficacy, offering an evidence-based model for delivering comprehensive survivorship care.

Implications for Cancer Survivors

The ThrivePath program provides a practical and accessible tool for survivors to manage their health following active treatment. By facilitating access to evidence-based resources and enabling direct communication with a care team, the program can help alleviate persistent symptoms, build confidence in self-management, and improve overall quality of life during the transition to survivorship.

Trial registration: ChiCTR2500108128.